Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Regulation of hTERT by BCR-ABL at multiple levels in K562 cells

Authors: Juin Hsien Chai, Yong Zhang, Wei Han Tan, Wee Joo Chng, Baojie Li, Xueying Wang

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells.

Methods

Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels.

Results

Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec.

Conclusions

Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.
Appendix
Available only for authorised users
Literature
1.
2.
Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E: Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986, 47 (2): 277-284. 10.1016/0092-8674(86)90450-2.CrossRefPubMed
3.
Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, Crist W, Rovera G, Smith SD, Witte ON: Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 1988, 239 (4841 Pt 1): 775-777.CrossRefPubMed
4.
Rowley JD: Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243 (5405): 290-293. 10.1038/243290a0.CrossRefPubMed
5.
Butturini A, Arlinghaus RB, Gale RP: BCR/ABL. Encyclopedia of Cancer. 2002, 1: 6-
6.
Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007, 7 (6): 441-453. 10.1038/nrc2147.CrossRefPubMed
7.
Mandanas RA, Leibowitz DS, Gharehbaghi K, Tauchi T, Burgess GS, Miyazawa K, Jayaram HN, Boswell HS: Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood. 1993, 82 (6): 1838-1847.PubMed
8.
Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, et al: Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3 k/Akt-dependent pathway. EMBO J. 1997, 16 (20): 6151-6161. 10.1093/emboj/16.20.6151.CrossRefPubMedPubMedCentral
9.
Raitano AB, Halpern JR, Hambuch TM, Sawyers CL: The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci USA. 1995, 92 (25): 11746-11750. 10.1073/pnas.92.25.11746.CrossRefPubMedPubMedCentral
10.
Sawyers CL, Callahan W, Witte ON: Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992, 70 (6): 901-910. 10.1016/0092-8674(92)90241-4.CrossRefPubMed
11.
Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990, 247 (4946): 1079-1082. 10.1126/science.2408149.CrossRefPubMed
12.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2 (5): 561-566. 10.1038/nm0596-561.CrossRefPubMed
13.
John S: The molecular biology of cancer. Molecular Aspects of Medicine. 2001, 21: 57-
14.
O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM: Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 2003, 17 (3): 481-487. 10.1038/sj.leu.2402848.CrossRefPubMed
15.
Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR: Protein composition of catalytically active human telomerase from immortal cells. Science. 2007, 315 (5820): 1850-1853. 10.1126/science.1138596.CrossRefPubMed
16.
17.
Bock O, Serinsoz E, Schlue J, Kreipe H: Different expression levels of the telomerase catalytic subunit hTERT in myeloproliferative and myelodysplastic diseases. Leuk Res. 2004, 28 (5): 457-460. 10.1016/j.leukres.2003.09.006.CrossRefPubMed
18.
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature. 1999, 400 (6743): 464-468. 10.1038/22780.CrossRefPubMed
19.
Aisner DL, Wright WE, Shay JW: Telomerase regulation: not just flipping the switch. Curr Opin Genet Dev. 2002, 12 (1): 80-85. 10.1016/S0959-437X(01)00268-4.CrossRefPubMed
20.
Kang SS, Kwon T, Kwon DY, Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 1999, 274 (19): 13085-13090. 10.1074/jbc.274.19.13085.CrossRefPubMed
21.
Liu JP: Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. 1999, 13 (15): 2091-2104.PubMed
22.
Lankat-Buttgereit B, Horsch D, Barth P, Arnold R, Blocker S, Goke R: Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion. 2005, 71 (3): 131-140. 10.1159/000084647.CrossRefPubMed
23.
Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, et al: Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer. 2005, 92 (10): 1881-1891. 10.1038/sj.bjc.6602592.CrossRefPubMedPubMedCentral
24.
Wihlidal P, Karlic H, Pfeilstocker M, Klaushofer K, Varga F: Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines. Leuk Res. 2008, 32 (3): 437-443. 10.1016/j.leukres.2007.07.020.CrossRefPubMed
25.
Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G: Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. Exp Hematol. 2010, 38 (1): 27-37. 10.1016/j.exphem.2009.10.005.CrossRefPubMed
26.
Campbell LJ, Fidler C, Eagleton H, Peniket A, Kusec R, Gal S, Littlewood TJ, Wainscoat JS, Boultwood J: hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia. 2006, 20 (4): 671-679. 10.1038/sj.leu.2404141.CrossRefPubMed
27.
28.
Baird DM, Rowson J, Wynford-Thomas D, Kipling D: Extensive allelic variation and ultrashort telomeres in senescent human cells. Nat Genet. 2003, 33 (2): 203-207. 10.1038/ng1084.CrossRefPubMed
29.
Opitz OG: Telomeres, telomerase and malignant transformation. Curr Mol Med. 2005, 5 (2): 219-226. 10.2174/1566524053586626.CrossRefPubMed
30.
Capdeville R, Buchdunger E, Zimmermann J, Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002, 1 (7): 493-502. 10.1038/nrd839.CrossRefPubMed
31.
Hartmann U, Balabanov S, Ziegler P, Fellenberg J, van der Kuip H, Duyster J, Lipp HP, Bokemeyer C, Kanz L, Brummendorf TH: Telomere length and telomerase activity in the BCR-ABL-transformed murine pro-B cell line BaF3 is unaffected by treatment with imatinib. Experimental Hematology. 2005, 33 (5): 542-549. 10.1016/j.exphem.2005.02.002.CrossRefPubMed
32.
Yi X, Shay JW, Wright WE: Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 2001, 29 (23): 4818-4825. 10.1093/nar/29.23.4818.CrossRefPubMedPubMedCentral
33.
Bellon M, Nicot C: Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells. Blood. 2008, 112 (7): 2946-2955. 10.1182/blood-2008-01-134692.CrossRefPubMedPubMedCentral
34.
Nakatake M, Kakiuchi Y, Sasaki N, Murakami-Murofushi K, Yamada O: STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells. Cell Cycle. 2007, 6 (12): 1496-1501.CrossRefPubMed
35.
Horikawa I, Cable PL, Mazur SJ, Appella E, Afshari CA, Barrett JC: Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol Biol Cell. 2002, 13 (8): 2585-2597. 10.1091/mbc.E01-11-0107.CrossRefPubMedPubMedCentral
36.
Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M: STAT5 contributes to interferon resistance of melanoma cells. Curr Biol. 2005, 15 (18): 1629-1639. 10.1016/j.cub.2005.08.036.CrossRefPubMed
37.
Liu K, Hodes RJ, Weng N: Cutting edge: telomerase activation in human T lymphocytes does not require increase in telomerase reverse transcriptase (hTERT) protein but is associated with hTERT phosphorylation and nuclear translocation. J Immunol. 2001, 166 (8): 4826-4830.CrossRefPubMed
38.
Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, Fruman DA: Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL + leukemia cells. J Clin Invest. 2008, 118 (9): 3038-3050. 10.1172/JCI33337.CrossRefPubMedPubMedCentral
39.
Darnell JE, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994, 264 (5164): 1415-1421. 10.1126/science.8197455.CrossRefPubMed
40.
Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene. 2000, 19 (21): 2474-2488. 10.1038/sj.onc.1203527.CrossRefPubMed
41.
Ye D, Wolff N, Li L, Zhang SM, Ilaria RL: STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood. 2006, 107 (12): 4917-4925. 10.1182/blood-2005-10-4110.CrossRefPubMedPubMedCentral
42.
Ilaria RL, Van Etten RA: P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996, 271 (49): 31704-31710. 10.1074/jbc.271.49.31704.CrossRefPubMed
43.
Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL: Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996, 13 (2): 247-254.PubMed
44.
Decker T, Kovarik P: Transcription factor activity of STAT proteins: structural requirements and regulation by phosphorylation and interacting proteins. Cell Mol Life Sci. 1999, 55 (12): 1535-1546. 10.1007/s000180050393.CrossRefPubMed
45.
Hoelbl A, Schuster C, Kovacic B, Zhu BM, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, et al: Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Molecular Medicine. 2010, 2 (3): 98-110. 10.1002/emmm.201000062.CrossRefPubMedPubMedCentral
46.
Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD: STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000, 95 (6): 2118-2125.PubMed
47.
Lin JX, Leonard WJ: The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000, 19 (21): 2566-2576. 10.1038/sj.onc.1203523.CrossRefPubMed
48.
Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang DM, Brown M, Bodner S, Grosveld G, Ihle JN: Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998, 93 (5): 841-850. 10.1016/S0092-8674(00)81444-0.CrossRefPubMed
49.
Socolovsky M, Fallon AEJ, Wang S, Brugnara C, Lodish HF: Fetal anemia and apoptosis of red cell progenitors in Stat5a(-/-)5b(-/-) mice: A direct role for Stat5 in Bcl-X-L induction. Cell. 1999, 98 (2): 181-191. 10.1016/S0092-8674(00)81013-2.CrossRefPubMed
50.
Liu XW, Robinson GW, Wagner KU, Garrett L, WynshawBoris A, Hennighausen L: Stat5a is mandatory for adult mammary gland development and lactogenesis. Gene Dev. 1997, 11 (2): 179-186. 10.1101/gad.11.2.179.CrossRefPubMed
51.
Park SH, Liu X, Hennighausen L, Davey HW, Waxman DJ: Distinctive roles of STAT5a and STAT5b in sexual dimorphism of hepatic P450 gene expression. Impact of STAT5a gene disruption. J Biol Chem. 1999, 274 (11): 7421-7430. 10.1074/jbc.274.11.7421.CrossRefPubMed
52.
Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, et al: The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood. 2011, 117 (12): 3421-3429. 10.1182/blood-2009-11-255232.CrossRefPubMedPubMedCentral
53.
Warsch W, Kollmann K, Eckelhart E, Fajmann S, Cerny-Reiterer S, Holbl A, Gleixner KV, Dworzak M, Mayerhofer M, Hoermann G, et al: High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011, 117 (12): 3409-3420. 10.1182/blood-2009-10-248211.CrossRefPubMed
54.
Liu JP: Protein phosphorylation events in exocytosis and endocytosis. Clin Exp Pharmacol Physiol. 1997, 24 (8): 611-618. 10.1111/j.1440-1681.1997.tb02101.x.CrossRefPubMed
55.
Li H, Zhao LL, Funder JW, Liu JP: Protein phosphatase 2A inhibits nuclear telomerase activity in human breast cancer cells. J Biol Chem. 1997, 272 (27): 16729-16732. 10.1074/jbc.272.27.16729.CrossRefPubMed
56.
Kharbanda S, Kumar V, Dhar S, Pandey P, Chen C, Majumder P, Yuan ZM, Whang Y, Strauss W, Pandita TK, et al: Regulation of the hTERT telomerase catalytic subunit by the c-Abl tyrosine kinase. Curr Biol. 2000, 10 (10): 568-575. 10.1016/S0960-9822(00)00483-8.CrossRefPubMed
57.
Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006, 108 (7): 2332-2338. 10.1182/blood-2006-02-004580.CrossRefPubMedPubMedCentral
58.
Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A, Eder M: Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood. 2006, 107 (8): 3279-3287. 10.1182/blood-2005-08-3087.CrossRefPubMed
59.
Donato NJ, Wu JY, Zhang L, Kantarjian H, Talpaz M: Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition. Blood. 2001, 97 (9): 2846-2853. 10.1182/blood.V97.9.2846.CrossRefPubMed
Metadata
Title
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells
Authors
Juin Hsien Chai
Yong Zhang
Wei Han Tan
Wee Joo Chng
Baojie Li
Xueying Wang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-512

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Study protocol

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

Research article

Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Research article

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

Research article

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Research article

Loss of aquaporin-4 expression and putative function in non-small cell lung cancer

Research article

Molecular cytogenetic characterization of canine histiocytic sarcoma: A spontaneous model for human histiocytic cancer identifies deletion of tumor suppressor genes and highlights influence of genetic background on tumor behavior
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits